Abstract
Chronic obstructive pulmonary disease (COPD) causes considerable morbidity, but appropriate drug therapy can reduce symptoms and exacerbations and can result in improved quality of life for patients. The mainstays of symptomatic treatment are beta2-agonist bronchodilators (β2-agonists) and/or anticholinergic bronchodilators. Long-acting β2-agonist and anticholinergic bronchodilators have been shown to reduce exacerbation ates in clinical trials. Inhaled corticosteroids may also reduce exacerbation rates in patients with moderate-to-severe disease and combination inhaled corticosteroid and long-acting β2-agonist inhalers have recently been licensed for use in COPD.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
